Showing 6571-6580 of 6948 results for "".
- Cosmetic Surgery Forum Announces Innovators in Dermatology Recipientshttps://practicaldermatology.com/news/20131107-cosmetic_surgery_forum_announces_innovators_in_dermatology_recipients/2459420/The upcoming Cosmetic Surgery Forum (www.cosmeticsurgeryforum.com), taking place at the ARIA Resort and Casino in Las Vegas from December 5-7, recently announced the recipients of its “Innovators in Dermatology” presentation. Among those honored this year will be Jim Hartman, Vice President of US Ae
- MELA Sciences Appoints Rose Crane as President and Chief Executive Officer and a Directorhttps://practicaldermatology.com/news/20131106-mela_sciences_appoints_rose_crane_as_president_and_chief_executive_officer_and_a_director/2459422/MELA Sciences, Inc. (MELA), the medical device company that has developed and is commercializing MelaFind(R), an optical diagnostic device using proprietary technology that enables dermatologists to “see” below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced that
- Juvéderm Voluma XC Approved in UShttps://practicaldermatology.com/news/20131023-juvderm_voluma_xc_approved_in_us/2459431/The FDA has approved Juvéderm Voluma XC (Allergan), the first injectable filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. The approval is based on a pivotal clinical trial in the US and Canada demonstrating that Juvéderm Vol
- Novartis Announced Positive Phase III Psoriasis Results for Secukinumabhttps://practicaldermatology.com/news/20131021-novartis_announced_positive_phase_iii_psoriasis_results_for_secukinumab/2459432/Novartis announced results from its head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to etanercept (Enbrel) in moderate-to-severe
- FDA Files sBLA for Xolair in Patients with Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20131011-genentech_files_sbla_for_xoliar_in_patients_with_cronic_idiopathic_urticaria/2459437/The FDA accepted and filed Genentech's supplemental Biologics License Application (sBLA) for subcutaneous use of Xolair® (omalizumab) in people with Chronic Idiopathic Urticaria (CIU) who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses. The filing was primarily
- ALPHAEON Acquires Exclusive Worldwide Licensing Rights To TouchMDhttps://practicaldermatology.com/news/20131010-alphaeon_acquires_exclusive_worldwide_licensing_rights_to_touchmd/2459439/ALPHAEON Corp., a leader in lifestyle healthcare and wholly-owned subsidiary of Strathspey Crown Holdings LLC, announced today that it has acquired worldwide licensing rights to TouchMD, for an undisclosed amount. TouchMD is an interactive software platform that helps speciality physicians educate p
- KYTHERA Biopharmaceuticals Announces Proposed Public Offering of Common Stockhttps://practicaldermatology.com/news/20131007-kythera_biopharmaceuticals_announces_proposed_public_offering_of_common_stock/2459441/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $100 million. All of the shares of the common stock to be sold in the offering will be offered by KYTHERA. KYTHERA intend
- Strathspey Crown's Alphaeon Acquires Toxin Developer Evolus, Inc.https://practicaldermatology.com/news/20131004-strathspey_crowns_alphaeon_acquires_toxin_developer_evolus_inc/2459443/Strathspey Crown Holdings, LLC has acquired Evolus, Inc. of Santa Barbara, California for an undisclosed amount. As part of the transaction, Strathspey Crown's wholly-owned subsidiary, Alph
- MELA Sciences Appoints Dr. Darrell Rigel as Chief Medical Advisor to Its Board of Directorshttps://practicaldermatology.com/news/20131001-mela_sciences_appoints_dr_darrell_rigel_as_chief_medical_advisor_to_its_board_of_directors/2459445/MELA Sciences, Inc., announced that Darrell S. Rigel, MD, MS, Clinical Professor of Dermatology at New York University, Langone Medical Center, has been appointed Chief Medical Advisor to the Company's Board of Directors. Dr. Rigel is a Clinical Profes
- Dermatologist Launches Sunscreen with Zinc, Anti-cancer Agentshttps://practicaldermatology.com/news/20130926-dermatologist_launches_sunscreen_with_zinc_anti-cancer_agents/2459449/Rejuve MD is an anti-aging sunblock that includes only Zinc Oxide as the sunblock without the need to use chemical sunscreens. Rejuve MD sunblock is also unique in that it not only prevents UV radiation sun damage from both UVB but also UVA light and it also has anti-aging and anti-cancer forming na